What it's for (Indications)
- Gliclazide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is typically considered when diet, exercise, and weight reduction alone are insufficient to achieve adequate blood glucose levels.
- Gliclazide works to lower blood sugar by stimulating the pancreas to produce more insulin.
- It should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it is dependent on the presence of functioning pancreatic beta cells.
- Its efficacy is primarily observed in managing postprandial hyperglycemia and reducing fasting plasma glucose levels, contributing to overall HbA1c reduction.
- It is a suitable option for patients who require oral therapy to manage their blood glucose levels effectively.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of gliclazide must be individualized based on the patient's blood glucose levels and response to therapy, always initiated at the lowest effective dose. For immediate-release (IR) formulations, the usual initial dose is 40-80 mg daily, taken with breakfast. The dose may be titrated gradually, usually in increments of 40-80 mg, at intervals of at least 14 days, based on glycemic response. The maximum daily dose for IR formulation is typically 320 mg, divided into two doses if exceeding 160 mg. For modified-release (MR) formulations, the usual initial dose is 30 mg once daily, taken with breakfast. The dose may be titrated in increments of 30 mg, based on glycemic response, at intervals of at least one month (or shorter intervals if glycemic control is not improving after 2 weeks and blood glucose is consistently high). The maximum daily dose for MR formulation is typically 120 mg, taken as a single dose. Dosing should always be taken with food to minimize gastrointestinal upset and ensure consistent absorption. Renal and hepatic impairment necessitate careful dose adjustments and monitoring to prevent hypoglycemia, often requiring lower starting doses and closer surveillance. |
Safety & Warnings
Common Side Effects
- The most common and clinically significant side effect associated with gliclazide, like other sulfonylureas, is hypoglycemia.
- Symptoms can include sweating, intense hunger, tremor, dizziness, headache, blurred vision, confusion, irritability, and in severe cases, loss of consciousness or seizures.
- Gastrointestinal disturbances such as nausea, dyspepsia, vomiting, diarrhea, and constipation are also reported, though typically mild and transient.
- Dermatological reactions like rash, pruritus, erythema, and urticaria can occur, and in rare instances, more severe cutaneous reactions.
- Less frequently, hepatic enzyme elevations (transient), cholestatic jaundice, and hematological abnormalities such as leukopenia, thrombocytopenia, agranulocytosis, and aplastic anemia have been observed.
- Weight gain is a known effect of sulfonylurea therapy due to increased insulin levels.
- Patients should be educated on recognizing and managing hypoglycemic episodes, especially given the potential for severe consequences.
- Allergic reactions, including angioedema, though rare, warrant immediate medical attention.
Serious Warnings
- Black Box Warning: Serious Warnings: Risk of Severe Hypoglycemia Gliclazide, like other sulfonylurea agents, carries a significant risk of inducing severe hypoglycemia. This serious adverse event can manifest as prolonged or intractable hypoglycemia, requiring hospitalization and specialized medical management. Elderly patients, individuals with impaired renal or hepatic function, those who are malnourished, or patients receiving concurrent medications that can potentiate the hypoglycemic effect of gliclazide (e.g., certain antifungals, NSAIDs, beta-blockers) are at a particularly elevated risk. In some cases, severe hypoglycemia can lead to permanent neurological damage, coma, or even death. Patients and caregivers must be thoroughly educated on the signs and symptoms of hypoglycemia, appropriate management strategies (e.g., consumption of simple carbohydrates), and when to seek immediate medical attention. Regular self-monitoring of blood glucose is critical to prevent and detect hypoglycemic episodes early. Dose adjustment and careful monitoring are imperative, especially when initiating therapy, titrating the dose, or changing concomitant medications. The potential for nocturnal or asymptomatic hypoglycemia further emphasizes the need for vigilance and patient education, ensuring a clear understanding of the risks associated with this medication.
- Patients receiving gliclazide are at significant risk of hypoglycemia, particularly the elderly, malnourished individuals, those with renal or hepatic impairment, or patients undergoing strenuous exercise without adequate caloric intake.
- Concomitant use with other hypoglycemic agents (e.
- g.
- , insulin, metformin, alpha-glucosidase inhibitors) or alcohol can significantly potentiate this risk.
- Careful patient selection, thorough education on hypoglycemia symptoms and management, and dose titration are crucial.
- The sulfonylurea class, in general, has been associated with an increased risk of cardiovascular mortality in the past (e.
- g.
- , UGDP study with first-generation sulfonylureas), although this association is less clear for second-generation agents like gliclazide.
- Nevertheless, cardiovascular risk factors should be managed diligently in all patients with type 2 diabetes.
- Gliclazide should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia.
- Regular monitoring of blood glucose and HbA1c is essential to ensure efficacy and detect primary or secondary failure of the drug.
- Patients experiencing stress, infection, trauma, or surgery may require temporary insulin therapy.
- Furthermore, patients should be advised about potential drug interactions, especially with other medications that can either potentiate (e.
- g.
- , certain antifungals like miconazole, NSAIDs, sulfonamides, beta-blockers, ACE inhibitors, warfarin) or antagonize (e.
- g.
- , corticosteroids, diuretics, thyroid hormones, oral contraceptives, phenothiazines) its hypoglycemic effect.
How it Works (Mechanism of Action)
Gliclazide is a second-generation sulfonylurea oral hypoglycemic agent that exerts its primary therapeutic effect by stimulating insulin release from the pancreatic beta cells. Its mechanism involves binding to specific sulfonylurea receptors (SUR1) on the beta cell membrane. This binding leads to the closure of ATP-sensitive potassium channels (KATP channels), which subsequently depolarizes the beta cell membrane. Depolarization opens voltage-dependent calcium channels, allowing an influx of calcium ions into the cell. The increased intracellular calcium concentration then triggers the exocytosis of insulin-containing granules, resulting in a rapid release of insulin into the bloodstream. Unlike some older sulfonylureas, gliclazide is also thought to have extrapancreatic effects, potentially improving insulin sensitivity in peripheral tissues and reducing hepatic glucose output, although its predominant action remains insulin secretion stimulation. It also possesses mild antioxidant properties, which may contribute to vascular protection. This action is dependent on the presence of functional beta cells within the pancreas and is thus ineffective in type 1 diabetes.